Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

ll six assessment periods, including Week 72, in CAPACITY 2, and at all four of the assessment periods through Week 48 in CAPACITY 1, but not at Week 72. An analysis of pooled data from the two CAPACITY studies showed that placebo-treated patients experienced a mean of 76 mL more decline in FVC than patients who received pirfenidone at Week 72. At Week 48, patients who received pirfenidone experienced a mean of 169 mL less FVC decline compared to placebo in CAPACITY 2 (p=0.002) and a mean of 54 mL less FVC decline in CAPACITY 1 (p=0.006). This pattern of change is consistent with that observed at Week 52 in the Phase 3 study of pirfenidone conducted by Shionogi.

Categorical Analysis of Change in Six-Minute Walk Test (6MWT) Distance

Post-hoc analyses of data from the 826-patient INSPIRE trial suggested that patients experiencing a 50-meter decrement in distance walked during the 6MWT at six months had an approximately 2.5-fold increased risk in mortality. Using this threshold, 33% and 47% of pirfenidone and placebo patients, respectively, in CAPACITY 1 (p=0.013), and 37% and 47% of pirfenidone and placebo patients, respectively, in CAPACITY 2 (p=0.032) experienced this magnitude of change. In a pooled analysis, 35% and 47% of pirfenidone and placebo patients, respectively, experienced a change that exceeded this threshold (p=0.001).

Safety and Tolerability Results

Safety data presented for both studies showed that pirfenidone given as 2403 mg per day was safe and generally well tolerated. In CAPACITY 2, 83% and 90% of surviving, lung transplant-free patients completed therapy per protocol in the pirfenidone and placebo groups, respectively, and 82% and 90%, respectively, of patients did so in CAPACITY 1. The percentage of patients discontinuing treatment due to an adverse event across both studies combined was 15% and 9% in the pirfenidone and placebo groups, respectively.

'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market ... Scanner Industry, 2009-2019 is a professional and in-depth ... Crystallography Scanner industry . The report firstly reviews ... its classification, application and manufacturing technology. The report ... X-Ray Crystallography Scanner listing their product specification, capacity, ...
(Date:8/29/2014)...  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), an ... services for the lawfully organized cannabis industry, is ... the Company,s name and symbol change request. Effective ... known as Chuma Holdings, Inc. ... with the Company,s wholly-owned subsidiary, Chuma Holdings, Inc., ...
(Date:8/29/2014)... , Aug. 29, 2014 The clinical ... can be the difference between a product,s success or ... map and stratify KOL targets – and then to ... type of strong relationships upon which successful KOL engagement ... pharma companies have identified internal inconsistencies in their KOL ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... clinical study to evaluate multiple ascending doses of NKTR-181, ... in development as a once- or twice-daily oral tablet ... to address the abuse liability and serious central nervous ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Intravenous ... http://www.reportlinker.com/p0611078/Global-Intravenous-IV-Solutions-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_E This report analyzes ... in US$ Million. The report provides separate ...
Cached Medicine Technology:Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6Global Intravenous (IV) Solutions Industry 2Global Intravenous (IV) Solutions Industry 3Global Intravenous (IV) Solutions Industry 4Global Intravenous (IV) Solutions Industry 5Global Intravenous (IV) Solutions Industry 6Global Intravenous (IV) Solutions Industry 7Global Intravenous (IV) Solutions Industry 8
(Date:8/30/2014)... 2014 The new review published by Daily ... by Karen Brimeyer, who wanted to make her guide accessible ... guide is now easy to find in the form of ... guide, the author of the new method shares all her ... Gossip writes in its review that the leaky gut syndrome ...
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... online reputation management industry, has announced to offer guarantee ... has decided to offer this guarantee because of its ... more than 200 clients from all over the world ... doing extremely good job. , On being asked ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 August 28th, ... shoulder pain in our society and the toll that ... costs, it’s vital that continuing education for physical therapists ... to help physical therapists help others, Hands-On Seminars is ... , Three learning styles are available to ...
(Date:8/30/2014)... LiveStreamingFitness.com, a company dedicated to providing live at home fitness ... to announce it has been recognized as one of the ... ABC’s Good Morning America. , As aired ... “Live Streaming Fitness is the hottest new trend in fitness. ... workout…to boot camp at Life Streaming Fitness for less than ...
(Date:8/30/2014)... Plains, NJ (PRWEB) August 30, 2014 Ms. ... for her. She certainly has an impressive resume to ... Trump’s Miss USA in 2012. However, she’s also a ... Pre-med Grad student. Nana trained for the 2008 Olympics ... official Miss USA website, “This six-foot beauty from Potomac, Maryland ...
Breaking Medicine News(10 mins):Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2
... Strictly embargoed until: 00.01 GMT, Friday, 12 October, ... world,s,maternal mortality ratio (the number of maternal deaths per ... Development Goal (MDG),5, which aims to improve maternal health ... While an annual decline of 5.5 per cent in ...
... Calif., Oct. 11 Each year, more than,90,000 ... of gynecological cancer.,Although the overall death rate for ... cancer has increased slightly. Dr. Stan Wasbin, ... provides an overview of gynecological,cancer, stressing the importance ...
... little,cooler for the patients at Children,s National Medical Center, ... will make their annual,visit. The team will also launch ... Caps., Courage Caps are team-issued and branded hats ... games and online at NHL.com, with,100 percent of the ...
... Cancer researchers have long worked to understand why some ... to stop the production of testosterone and other androgens ... detected that androgen-synthesizing proteins are present within cancer cells, ... to produce their own androgens. , The presence ...
... School of Medicine have found that professional welders who ... at risk for loss of sense of smell. ... the first study to clearly demonstrate that welders who ... at risk for damaging their sense of smell, says ...
... 11 Six earthbound "angels" who have,brightened the lives ... Shield of Michigan. The Caring for Children Angel ... children,s lives. The awards have been,sponsored annually by the ... be honored at a Friday, Nov. 9 reception and ...
Cached Medicine News:Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 2Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 3Health News:The Silent Killer, Ovarian Cancer on Your Cancer Today (TM) 2Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Penn study suggests professional welders at risk for loss of sense of smell 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 3
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... Akers, our ultimate goal is to provide ... and immediate treatment. Each year millions of ... die from late detection or undetected disease ... cripple nations., ,By developing, manufacturing and marketing ...
... BD Macro-Vue RPR (Rapid Plasma Reagin) ... Tests are nontreponemal testing procedures for ... in A Manual of Tests for ... manual are the most widely used ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Medicine Products: